Oriola
1,022
EUR
+3,65 %
OKDBV
NASDAQ Helsinki
Medical Equipment & Services
Health Care
7.661 følger denne virksomhed
+3,65%
+8,72%
+14,83%
+12,43%
+7,58%
-7,93%
-47,54%
-46,88%
-44,44%
Oriola is a pharmaceutical group with a special focus on the distribution of pharmaceuticals to other companies in the industry. The company offers services to pharmacies and other pharmaceutical companies, which includes, for example, negotiations with suppliers and distribution of products. The largest presence is in the Nordic and Baltic countries. The head office is located in Espoo.
Læs mereMarkedsværdi
185,48 mio. EUR
Aktieomsætning
293,04 t EUR
P/E (adj.) (24e)
27,29
EV/EBIT (adj.) (24e)
4,83
P/B (24e)
1,17
EV/S (24e)
0,06
Udbytteafkast, % (24e)
7,83 %
Omsætning og EBIT-margin
Omsætning mia.
EBIT-% (adj.)
EPS og udbytte
EPS (adj.)
Udbytte %
Finanskalender
4.3
2025
Årsrapport '24
2.4
2025
Generalforsamling '25
29.4
2025
Delårsrapport Q1'25
Risiko
Business risk
Valuation risk
Lav
Høj
ViserAlle indholdstyper
Oriola Oyj: Oriola appoints Stig Tornell as Executive Vice President, Sales
Oriola Oyj: Oriola Corporation to publish its Financial Statements Release 2024 on 4 March 2025
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Oriola Oyj: Oriola Corporation's shareholder's demand for including combination of share classes and directed issuance of shares without payment in the agenda of the Annual General Meeting

Oriola, Webcast, Q4'24
Oriola Oyj: Oriola acquires MedInfo ApS in Denmark to strengthen its Nordic footprint in medical information and patient support programmes
Oriola Oyj: Proposals of the Shareholders' Nomination Board of Oriola Corporation concerning the Board of Directors to be elected by the 2025 Annual General Meeting
Oriola Oyj: Oriola to record an impairment of approximately EUR 16 million related to its joint venture Kronans Apotek
Oriola Oyj: Oriola renews operating model and management team to accelerate strategy execution
Oriola Oyj: The Swedish Patent and Market Court rejected Apotekstjänst Sverige AB's appeal regarding the sale of Svensk dos AB

Oriola-KD Oyj, Q3'24
Oriola Oyj: Oriola Corporation's Interim Report January-September 2024
Oriola Oyj: Oriola Corporation to publish its Interim Report for January-September 2024 on 30 October 2024
Oriola Oyj: Change in Oriola Management Team: Hannes Hasselrot, Chief Commercial Officer, to leave Oriola
Oriola Oyj: Oriola appoints Tuomas Tiilikainen as Chief Supply Chain Officer
Oriola Oyj: Publication schedule for Oriola Corporation's financial reporting in 2025
Oriola Oyj: Oriola appoints Mats Danielsson as Chief Financial Officer
Oriola Oyj: Changes in Oriola's Management Team: Timo Leinonen and Petri Boman to leave Oriola

Oriola Q2’24: Sales growth in both segments
